NZ602119A - Peptide vaccines for cancers expressing tumor-associated antigens - Google Patents

Peptide vaccines for cancers expressing tumor-associated antigens

Info

Publication number
NZ602119A
NZ602119A NZ602119A NZ60211908A NZ602119A NZ 602119 A NZ602119 A NZ 602119A NZ 602119 A NZ602119 A NZ 602119A NZ 60211908 A NZ60211908 A NZ 60211908A NZ 602119 A NZ602119 A NZ 602119A
Authority
NZ
New Zealand
Prior art keywords
associated antigens
expressing tumor
peptide vaccines
cancers expressing
cancers
Prior art date
Application number
NZ602119A
Other languages
English (en)
Inventor
Tsunoda Takuya
Ohsawa Ryuji
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of NZ602119A publication Critical patent/NZ602119A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001122—Ephrin Receptors [Eph]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/422—Ephrin Receptors [Eph]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
NZ602119A 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens NZ602119A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90294907P 2007-02-21 2007-02-21
NZ591704A NZ591704A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens

Publications (1)

Publication Number Publication Date
NZ602119A true NZ602119A (en) 2014-03-28

Family

ID=39709837

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ602119A NZ602119A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens
NZ591704A NZ591704A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens
NZ579768A NZ579768A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing cadherin 3 tumor-associated antigens
NZ602122A NZ602122A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ591704A NZ591704A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens
NZ579768A NZ579768A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing cadherin 3 tumor-associated antigens
NZ602122A NZ602122A (en) 2007-02-21 2008-02-21 Peptide vaccines for cancers expressing tumor-associated antigens

Country Status (27)

Country Link
EP (20) EP2121731B1 (enExample)
JP (6) JP5239103B2 (enExample)
KR (8) KR20160045939A (enExample)
CN (4) CN101663315B (enExample)
AR (1) AR068302A1 (enExample)
AU (1) AU2008218463B2 (enExample)
BR (1) BRPI0808421B1 (enExample)
CA (3) CA2919248A1 (enExample)
CO (1) CO6190536A2 (enExample)
CY (2) CY1114590T1 (enExample)
DK (3) DK2121731T3 (enExample)
ES (6) ES2540893T3 (enExample)
HR (3) HRP20131044T1 (enExample)
IL (10) IL200478A (enExample)
MX (4) MX337417B (enExample)
MY (2) MY155029A (enExample)
NZ (4) NZ602119A (enExample)
PH (1) PH12014501642A1 (enExample)
PL (3) PL2476694T3 (enExample)
PT (2) PT2465864E (enExample)
RU (1) RU2464275C2 (enExample)
SG (3) SG10201909675QA (enExample)
SI (3) SI2121731T1 (enExample)
TW (5) TWI615403B (enExample)
UA (1) UA100372C2 (enExample)
WO (1) WO2008102557A1 (enExample)
ZA (1) ZA200905881B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660677A2 (en) 2003-08-20 2006-05-31 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
CN104356225B (zh) * 2007-08-20 2018-02-13 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
RU2011103199A (ru) 2008-06-30 2012-08-10 Онкотерапи Сайенс, Инк. (Jp) Антитела против cdh3, меченные радиоизотопной меткой, и их применение
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
NZ592461A (en) 2008-10-22 2012-12-21 Oncotherapy Science Inc Rab6kifl/kif20a epitope peptide and vaccines containing the same
TWI539160B (zh) 2008-12-05 2016-06-21 腫瘤療法 科學股份有限公司 Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
JP5728716B2 (ja) 2008-12-24 2015-06-03 オンコセラピー・サイエンス株式会社 Ｃ１ｏｒｆ５９ペプチドおよびそれを含むワクチン
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
US9017669B2 (en) 2009-12-28 2015-04-28 Oncotherapy Science, Inc. Anti-CDH3 antibodies and uses thereof
WO2011116026A2 (en) 2010-03-15 2011-09-22 The Board Of Trustees Of The University Of Illinois Inhibitors of beta integrin-g protein alpha subunit binding interactions
TW201627003A (zh) * 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
BR112013013158B1 (pt) * 2010-12-02 2020-04-28 Oncotherapy Science, Inc. composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
US9452182B2 (en) * 2011-12-14 2016-09-27 Board Of Regents, The University Of Texas System Collateral gene inactivation biomarkers and targets for cancer therapy
CN104168917A (zh) * 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
EP2872530A4 (en) * 2012-07-10 2016-04-06 Oncotherapy Science Inc KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
WO2014010232A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Ly6k epitope peptides for th1 cells and vaccines containing the same
HUE036243T2 (hu) * 2012-08-31 2018-06-28 Vasculead Inc PSF1-származék peptid
JP6283861B2 (ja) 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ｕｂｅ２ｔペプチドおよびそれを含むワクチン
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR20160029127A (ko) * 2013-07-12 2016-03-14 다이니뽄 스미토모 세이야쿠 가부시키가이샤 종양 항원 펩티드
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
PE20170286A1 (es) 2014-07-01 2017-03-30 Pfizer Diacuerpos heterodimericos biespecificos y sus usos
IL250235B (en) * 2014-08-04 2022-07-01 Oncotherapy Science Inc A peptide derived from urlc10 and a component containing it
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) * 2015-06-05 2018-11-02 复旦大学附属肿瘤医院 一组用于评估肺癌预后的基因及其应用
PT3436048T (pt) * 2016-03-31 2025-08-06 Biontech Us Inc Neoantigénios e métodos da sua utilização
CN110214144B (zh) * 2016-11-16 2023-05-02 深圳华大生命科学研究院 多肽及其应用
AU2018213890B2 (en) 2017-01-25 2023-07-20 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
JP7289289B2 (ja) * 2017-03-28 2023-06-09 ツェンラン・チュー 腫瘍性疾患を治療する方法
EP3666887A4 (en) * 2017-08-10 2021-09-01 Good T Cells, Inc. T-CELL ACTIVATION METHOD FOR CANCER TREATMENT
EP3754022A4 (en) * 2018-02-15 2021-09-29 National University Corporation Asahikawa Medical University CANCER ANTIGENIC PEPTIDE
KR102335916B1 (ko) * 2019-04-22 2021-12-08 한국과학기술연구원 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113117055A (zh) * 2019-12-31 2021-07-16 上海细胞治疗集团有限公司 一种特异性结合hla-a24分型的多肽组合物及应用
CN117143206B (zh) * 2023-08-03 2024-09-03 华南农业大学 Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2084180A1 (en) * 1991-12-11 1993-06-12 Paul P. Hung Expression of specific immunogens using viral antigens
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP0756627A1 (en) * 1994-04-15 1997-02-05 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
ATE319477T1 (de) 1995-08-03 2006-03-15 Univ Leiden Antigen presentierende bläschen, die von zellen ableiten
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
WO1998045433A1 (en) * 1997-04-04 1998-10-15 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1375515A3 (en) * 1997-10-07 2004-04-21 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same, and use thereof
US20070014787A1 (en) * 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
AU1220001A (en) * 1999-10-20 2001-04-30 Zymogenetics Inc. Novel proteins and polynucleotides encoding them
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
WO2002008765A2 (en) 2000-07-26 2002-01-31 Stanford University Basal cell markers in breast cancer and uses thereof
US6830885B1 (en) * 2000-08-18 2004-12-14 Phenogene Therapeutiques Inc. Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
US20040236091A1 (en) * 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
EP1517998A2 (en) * 2001-06-18 2005-03-30 EOS Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CN1653080A (zh) * 2002-03-07 2005-08-10 路德维格癌症研究院 淋巴管和血管的内皮细胞基因
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004055050A2 (en) * 2002-12-10 2004-07-01 Endocube Sas Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
AU2003297318A1 (en) * 2002-12-20 2004-07-22 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
TWI324608B (en) * 2003-02-28 2010-05-11 Oncotherapy Science Inc Genes and polypeptides relating to human colorectal cancers
WO2005001138A2 (en) * 2003-06-18 2005-01-06 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1660677A2 (en) * 2003-08-20 2006-05-31 Oncotherapy Science, Inc. Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
EP1730279A2 (en) * 2004-02-27 2006-12-13 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
JP4761389B2 (ja) * 2004-04-09 2011-08-31 株式会社ジーンケア研究所 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN100381460C (zh) * 2004-11-30 2008-04-16 北京市肿瘤防治研究所 Her-2模拟抗原表位及含有该表位的肽
CN101160524A (zh) * 2005-02-24 2008-04-09 西米尼斯公司 用于生物样品分类的组合物和方法
PT2325306E (pt) * 2005-02-25 2014-04-29 Oncotherapy Science Inc Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1
CN100348614C (zh) * 2005-06-03 2007-11-14 北京大学 一种肝癌－睾丸特异性抗原蛋白质和抗原肽
KR101304243B1 (ko) * 2005-08-09 2013-09-05 온코세라피 사이언스 가부시키가이샤 ＨＬＡ-Ａ2 양성 환자용 글리피칸-3(ｇｌｙｐｉｃａｎ-3)유래의 암 거절항원 펩티드 및 그를 포함하는 의약
EP1930427B1 (en) * 2005-08-09 2012-04-11 Kurume University Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
US20090263832A1 (en) * 2005-11-30 2009-10-22 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in Leukemia Signaling Pathways
CN103351425B (zh) * 2006-04-10 2016-01-20 健泰科生物技术公司 散乱蛋白pdz调节剂
CN103435683B (zh) * 2006-06-16 2016-02-03 肿瘤疗法·科学股份有限公司 来自sparc的癌排斥抗原肽以及含有该肽的药物
US20090081659A1 (en) * 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) * 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
CN104356225B (zh) * 2007-08-20 2018-02-13 肿瘤疗法科学股份有限公司 Cdh3 肽以及含有cdh3 肽的药剂
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
WO2011039289A1 (de) * 2009-09-29 2011-04-07 Protagen Ag Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

Also Published As

Publication number Publication date
HK1172345A1 (en) 2013-04-19
TW201422637A (zh) 2014-06-16
TWI494319B (zh) 2015-08-01
ES2527397T3 (es) 2015-01-23
EP2570430A2 (en) 2013-03-20
MX2009009022A (es) 2010-03-03
SG10201506589WA (en) 2015-09-29
KR101543623B1 (ko) 2015-08-11
EP2594581A2 (en) 2013-05-22
ES2435194T3 (es) 2013-12-16
IL219043A0 (en) 2012-05-31
EP2476695A2 (en) 2012-07-18
EP2567971A2 (en) 2013-03-13
EP2476694A3 (en) 2013-04-24
CA2678755C (en) 2016-04-26
KR20150116463A (ko) 2015-10-15
CN104292299B (zh) 2017-09-29
TW201623325A (zh) 2016-07-01
EP2476694A2 (en) 2012-07-18
CN103351423A (zh) 2013-10-16
EP2574623A3 (en) 2013-07-17
IL219042A0 (en) 2012-05-31
IL219042A (en) 2016-03-31
JP5239104B2 (ja) 2013-07-17
KR101644871B1 (ko) 2016-08-02
EP2573110A2 (en) 2013-03-27
EP2121731A4 (en) 2010-04-21
EP2570428A2 (en) 2013-03-20
ES2530777T3 (es) 2015-03-05
EP2476692B1 (en) 2015-04-15
IL219040A (en) 2014-12-31
IL219048A0 (en) 2012-05-31
JP2016094459A (ja) 2016-05-26
JP2014210804A (ja) 2014-11-13
IL219048A (en) 2015-07-30
EP2465867B1 (en) 2015-04-01
PL2121731T3 (pl) 2014-01-31
JP2010209060A (ja) 2010-09-24
JP5874158B2 (ja) 2016-03-02
CA2678755A1 (en) 2008-08-28
CN102863514A (zh) 2013-01-09
HK1134507A1 (en) 2010-04-30
RU2464275C2 (ru) 2012-10-20
CA2919248A1 (en) 2008-08-28
IL219040A0 (en) 2012-05-31
KR20140121489A (ko) 2014-10-15
IL219041A0 (en) 2012-05-31
KR101511140B1 (ko) 2015-04-10
BRPI0808421A2 (pt) 2017-08-29
CN104292299A (zh) 2015-01-21
AU2008218463A2 (en) 2009-11-26
CN102863514B (zh) 2014-12-10
JP2013116895A (ja) 2013-06-13
TWI610939B (zh) 2018-01-11
KR20150064236A (ko) 2015-06-10
CA2992074A1 (en) 2008-08-28
CO6190536A2 (es) 2010-08-19
TWI438207B (zh) 2014-05-21
DK2121731T3 (da) 2013-10-21
PT2121731E (pt) 2013-10-24
AU2008218463B2 (en) 2013-01-17
EP2465865A2 (en) 2012-06-20
SG179402A1 (en) 2012-04-27
MY155029A (en) 2015-08-28
EP2465866A3 (en) 2012-10-10
IL219045A0 (en) 2012-05-31
ES2541863T3 (es) 2015-07-27
EP2476694B1 (en) 2014-11-19
KR20150018895A (ko) 2015-02-24
NZ602122A (en) 2014-03-28
IL219046A0 (en) 2012-05-31
EP2121731A1 (en) 2009-11-25
EP2570429A2 (en) 2013-03-20
SI2465864T1 (sl) 2014-12-31
MX337417B (es) 2016-03-03
IL200478A (en) 2015-11-30
EP2594582A2 (en) 2013-05-22
SG10201909675QA (en) 2019-11-28
DK2476694T3 (en) 2014-12-08
ES2532708T3 (es) 2015-03-31
HRP20131044T1 (hr) 2013-12-06
EP2476693A3 (en) 2012-10-03
IL219044A0 (en) 2012-05-31
IL219041A (en) 2014-12-31
HK1172043A1 (en) 2013-04-12
MX359680B (es) 2018-09-28
EP2476693A2 (en) 2012-07-18
EP2465866A2 (en) 2012-06-20
HK1172041A1 (en) 2013-04-12
RU2009135020A (ru) 2011-03-27
KR101540000B1 (ko) 2015-07-29
IL219047A0 (en) 2012-05-31
UA100372C2 (ru) 2012-12-25
EP2465864A3 (en) 2012-10-03
IL219044A (en) 2014-12-31
CN101663315B (zh) 2014-10-15
EP2570429A3 (en) 2013-08-28
TW201433574A (zh) 2014-09-01
IL200478A0 (en) 2010-04-29
HRP20141233T1 (hr) 2015-02-27
EP2573109A2 (en) 2013-03-27
EP2476692A3 (en) 2012-12-19
EP2465864B1 (en) 2014-10-08
KR20090121349A (ko) 2009-11-25
HK1172344A1 (en) 2013-04-19
EP2570430A3 (en) 2013-07-10
CY1115841T1 (el) 2017-01-25
EP2465865A3 (en) 2013-07-24
EP2121731B1 (en) 2013-08-14
NZ579768A (en) 2012-03-30
EP2573109A3 (en) 2013-06-19
IL219043A (en) 2014-12-31
EP2594581A3 (en) 2013-08-14
CN103351423B (zh) 2016-09-28
IL219046A (en) 2015-02-26
HK1172346A1 (en) 2013-04-19
KR20130023407A (ko) 2013-03-07
CA2992074C (en) 2021-01-05
PL2476694T3 (pl) 2015-04-30
KR20140130507A (ko) 2014-11-10
CY1114590T1 (el) 2016-10-05
SI2476694T1 (sl) 2015-02-27
AR068302A1 (es) 2009-11-11
JP5614761B2 (ja) 2014-10-29
EP2594582A3 (en) 2013-08-14
TW201538522A (zh) 2015-10-16
MY173379A (en) 2020-01-21
EP2574623A2 (en) 2013-04-03
WO2008102557A1 (en) 2008-08-28
KR101644877B1 (ko) 2016-08-03
TW200844111A (en) 2008-11-16
EP2583976A3 (en) 2013-10-23
JP5608953B2 (ja) 2014-10-22
EP2465864A2 (en) 2012-06-20
DK2465864T3 (en) 2014-11-24
EP2476695A3 (en) 2012-12-12
PH12014501642B1 (en) 2015-12-02
EP2583976A2 (en) 2013-04-24
AU2008218463A1 (en) 2008-08-28
EP2567971A3 (en) 2013-06-26
EP2465867A2 (en) 2012-06-20
TWI596109B (zh) 2017-08-21
HK1172042A1 (en) 2013-04-12
HRP20150108T1 (hr) 2015-05-08
EP2465865B1 (en) 2016-11-02
TWI615403B (zh) 2018-02-21
MX337456B (es) 2016-03-03
ZA200905881B (en) 2010-05-26
EP2476693B1 (en) 2014-12-24
EP2570428A3 (en) 2013-07-10
EP2565203A1 (en) 2013-03-06
BRPI0808421B1 (pt) 2021-10-05
EP2465867A3 (en) 2012-10-10
KR101511134B1 (ko) 2015-04-28
PT2465864E (pt) 2015-01-14
PL2465864T3 (pl) 2015-03-31
NZ591704A (en) 2012-09-28
PH12014501642A1 (en) 2015-12-02
ES2540893T3 (es) 2015-07-14
EP2573110A3 (en) 2013-09-04
JP2013091645A (ja) 2013-05-16
JP2010519176A (ja) 2010-06-03
SI2121731T1 (sl) 2013-10-30
EP2476692A2 (en) 2012-07-18
KR20160045939A (ko) 2016-04-27
JP5239103B2 (ja) 2013-07-17
CN101663315A (zh) 2010-03-03

Similar Documents

Publication Publication Date Title
NZ602119A (en) Peptide vaccines for cancers expressing tumor-associated antigens
UA110473C2 (uk) Спосіб лікування раку за допомогою пухлиноасоційованого антигену, отриманого із цикліну d1
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
EP3447140A3 (en) Receptor gene for peptide cancer antigen-specific t cell
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
NZ598932A (en) Identification of antigenic peptides from multiple myeloma cells
MX2009007261A (es) Vacuna de peptido foxp3.
MX2010005816A (es) Epítopos de péptido de stat3.
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
CA2819463C (en) Tomm34 peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
WO2003091383A3 (fr) Epitopes t de l'antigene epha2.
SG10201408245WA (en) Tmem22 peptides and vaccines including the same
MX342000B (es) Peptidos ect2 y vacunas que los incluyen.
EP4047009A3 (en) Wdrpuh epitope peptides and vaccines containing the same
EP2545171A4 (en) HJURP PEPTIDES AND VACCINES CONTAINING THEM
WO2008092134A3 (en) Tumor-specific antigens, cytotoxic t lymphocytes responsive thereto, and methods of using the same
WO2009149094A3 (en) Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
NZ600763A (en) Vaccines and vaccine components for inhibition of microbial cells

Legal Events

Date Code Title Description
S23 Proceedings under section 23: mention of inventor as such in patent

Free format text: INVENTOR RYUJI OHSAWA, TAKUYA TSUNODA ADDED

Effective date: 20130221

AABA Application abandoned
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 FEB 2015 BY DENNEMEYER + CO

Effective date: 20140821

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 FEB 2016 BY DENNEMEYER + CO

Effective date: 20141219

LAPS Patent lapsed